Curis (CRIS) Tops Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Pre-Open Stock Movers 03/25: (CRIS) (AVYA) (AIMT) Higher; (PTI) (REPH) (AKAM) Lower (more...)
March 25, 2019 9:26 AM EDTToday's Pre-Open Movers
Curis, Inc. (NASDAQ: CRIS) 81% HIGHER; entered into an agreement with funds managed by Oberland Capital Management, LLC for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Proteostasis Therapeutics, Inc. (NASDAQ: PTI) 53.3% LOWER; announced results from Phase 1 clinical studies of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR)... More
Curis (CRIS) Sells Portion of Erivedge Royalties for up to $135.7 million
March 25, 2019 8:31 AM EDTCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Under the terms of the agreement, Curis... More
